-+ 0.00%
-+ 0.00%
-+ 0.00%
Optimi Health Advances Psilocybin, MDMA Clinical Programs; Phase 2b MDD Trial Dosing Set For Q1 2027
Share
Listen to the news

Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028

Health Canada-cleared Phase 3 trial of OPTI-201 MDMA-assisted therapy in 100 veterans and front-line workers with PTSD expected to begin in 2027; Company plans to file a U.S. IND for OPTI-201 in addition to the proposed Canadian trial.

VANCOUVER, British Columbia, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ:OPTH, CSE:OPTI, FSE: 8BN))) (the "Company" or "Optimi"), a commercial-stage pharmaceutical drug developer and manufacturer of regulated psychedelic drug products, provides an update on its clinical programs, commercial supply, Ibogaine Initiative and a shares-for-debt settlement.

Highlights

OPTI-101: naturally derived psilocybin for major depressive disorder (MDD)

Phase 2b Trial: randomized, double-blind, active placebo-controlled trial in 200 adults with severe MDD; dosing expected to begin in Q1 2027; topline data expected in 2028.

U.S. FDA Pathway: preparing an IND for the FDA ahead of a planned U.S. Phase 3 trial for the same indication.

Natural Psilocybin Alternative: positioned as a naturally derived alternative to the synthetic psilocybin products advancing toward FDA approval.

OPTI-201: MDMA for post-traumatic stress disorder (PTSD)

Phase 3 Trial: Health Canada-cleared study in 100 veterans and front-line workers; initiation expected in 2027.

MDMA Market Opportunity: prescribed in Australia since October 2024; positioned to enter the U.S. if MDMA-assisted therapy is approved.

Potential U.S. FDA Pathway: IND filing with the FDA planned for 2027, alongside initiation of the Canadian Phase 3.

Ibogaine Initiative

Finished-dose capsules: first in-house production expected in the coming weeks, in various dosage strengths, for prospective ARPA-H-funded research.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending